ASGTX
Price
$4.80
Change
-$0.09 (-1.84%)
Updated
Aug 28 closing price
Net Assets
84.12M
WCMNX
Price
$14.70
Change
-$0.28 (-1.87%)
Updated
Aug 28 closing price
Net Assets
50.65M
Interact to see
Advertisement

ASGTX vs WCMNX

ASGTX vs WCMNX Comparison Chart in %
View a ticker or compare two or three
VS
ASGTX vs. WCMNX commentary
Aug 31, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASGTX is a Hold and WCMNX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
ASGTX has more cash in the bank: 84.1M vs. WCMNX (50.6M). ASGTX (0.00) and WCMNX (0.00) have matching dividends . ASGTX was incepted earlier than WCMNX: ASGTX (14 years) vs WCMNX (7 years). WCMNX (2.04) is less costly to investors than ASGTX (1.54). WCMNX is a more actively managed with annual turnover of: 89.00 vs. ASGTX (47.00). ASGTX (1000) and WCMNX (1000) have matching initial minimum investment requirements. WCMNX annual gain was more profitable for investors over the last year : 8.97 vs. ASGTX (-11.44). WCMNX return over 5 years is better than : -5.53 vs. ASGTX (-46.07).
ASGTXWCMNXASGTX / WCMNX
Total Expense Ratio1.401.24113%
Annual Report Gross Expense Ratio1.542.0475%
Fund Existence14 years7 years-
Gain YTD5.0338.48759%
Front Load6%N/A-
Min. Initial Investment10001000100%
Min. Initial Investment IRAN/AN/A-
Net Assets84.1M50.6M166%
Annual Yield % from dividends0.000.00-
Returns for 1 year-11.448.97-128%
Returns for 3 years-21.4425.53-84%
Returns for 5 years-46.07-5.53833%
Returns for 10 years-62.44N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ANAVX29.510.01
+0.03%
Virtus NFJ International Value R6
PAARX17.99-0.07
-0.39%
Franklin Dynamic Asset Allocation Bal R
SLARX39.93-0.30
-0.75%
DWS Latin America Equity Inst
HFDRX21.66-0.18
-0.82%
Hartford Schroders US MidCap Opps R3
JGTUX42.36-0.55
-1.28%
JPMorgan Growth Advantage R4